Lawmakers across the political divide have accused the pharma industry of abusing the patent system to keep the prices of their products as high as possible in a combative
Artificial intelligence (AI) is revolutionising industries. But with this exciting new frontier comes a complex challenge: protecting your intellectual property (IP).
The European Commission has pulled marketing authorisations for generic versions of Biogen’s oral multiple sclerosis therapy Tecfidera, after concluding that the brand qua
The long-running legal dispute between Amgen and Sanofi/Regeneron on two key patents covering the use of PCSK9 inhibitors to lower cholesterol has come to an end, with San